The objective of this Registry is to collect real-world outcome data for bronchial thermoplasty (BT) procedures in patients with severe persistent asthma who remain symptomatic despite taking standard of care maintenance medications.
Data will be used to confirm the impact of BT on safety, effectiveness, quality of life, and the anticipated reduction in healthcare utilization events and cost by way of a reduction in severe asthma exacerbations.
Study Type
OBSERVATIONAL
Enrollment
225
The Alair system is used for doing bronchial thermoplasty.
BSC International Medical Trading (Shanghai) Co., Ltd.
Shanghai, Shanghai Municipality, China
Incidence of severe asthma exacerbations following BT with the Alair System.
Severe asthma exacerbation is defined as worsening of asthma symptoms requiring use of systemic corticosteroids (tablets, suspension, or injection) (NAEPP Guidelines, 2007). For patients already taking oral corticosteroids on a daily or alternate day basis, a severe asthma exacerbation is defined as a worsening of asthma symptoms requiring any increase in daily dose of systemic corticosteroids. For consistency, courses of corticosteroids separated by 1 week or more will be treated as separate severe exacerbations.
Time frame: 1 year
Quarlity of life of Patients
Asthma Quality of Life Questionnaire (AQLQ) score Asthma Control Questionnaire(ACQ)
Time frame: 1 year
Health care utilization
Emergency Department Visits,Hospitalizations,Unscheduled office visits including urgent care visits
Time frame: 1 year
FEV1
Pre- and post-bronchodilator FEV1
Time frame: 1 year
Serious respiratory adverse events
Rates of and proportion of patients with serious respiratory adverse events
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.